1 Erratum to: Drugs (2014) 74:1769–1784 DOI 10.1007/s40265-014-0298-1
Page 1777, column 2, section 4.4, paragraph 2, lines 3–8: The following sentence, which previously read:
“At 52 weeks, adjusted mean changes from baseline in daily insulin dose were significantly lower in the empagliflozin 10 and 25 mg groups than in the placebo group (+1.3 and −1.1 vs. +10.2 IU/day; both p < 0.01); respective baseline mean daily doses were 90.4, 89.4 and 99.5 IU/day [38].”
should read:
“At 78 weeks, adjusted mean changes from baseline in daily insulin dose were significantly lower in the empagliflozin 10 and 25 mg groups than in the placebo group (−1.21 and −0.47 vs. +5.45 IU/day; both p < 0.01); respective baseline mean daily doses were 45.13, 48.43 and 47.84 IU/day [38].”
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40265-014-0298-1.
Rights and permissions
About this article
Cite this article
Scott, L.J. Erratum to: Empagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 75, 141 (2015). https://doi.org/10.1007/s40265-014-0336-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-014-0336-z